Canada markets closed

Small Pharma Inc. (DMTTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0927-0.0033 (-3.40%)
At close: 03:54PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • C
    Chris
    this firm hasn't had a green day in about two months. that isn't a joke.
  • C
    Charles
    Big patent announcement today. Slow but steady wins the race.
  • C
    Chris
    pretty incredible at how terribly this trades
  • j
    j
    Hey All. Any body still paying attention to this stock. Comments seam to have gone to sleep.
  • J
    JUSTIN
    Any reason in particular for the 30% fall today?
  • T
    Tyler
    There’s still mega potential here. Very early stages
  • V
    V
    DMT has been so inconsistent as of late. Starting to feel like a pendulum.
  • C
    Chris
    it really doesn't help that Rand and his wife keep dumping shares.
  • T
    Travis
    Peter Rands presenting for Small Pharma right now at the Microdose DMT Conference
  • C
    CaudHenry
    “ The clinical trials began in January and if successful, the firm hopes to be able to start offering it as a licensed treatment in connection with therapy within six years.”
  • M
    Mike
    anybody here? whats everyones average
  • V
    V
    DMT is a hidden gem waiting to be discovered. One of the better psychedelic companies out there.
  • V
    V
    Will this ever make it back to 70 cents?
  • C
    Charles
    No one paying any attention to this stock. Yet it is up about 30% ytd.
  • M
    Mike
    Rands says that Small Pharma has an extensive patent portfolio, the bulk of which is in tryptamines and psychedelic tryptamines. 26 of their patent applications are related to psychedelic tryptamines. Many are focused on the DMT molecule without any functional changes to it.
    Rands adds that Small Pharma did develop a technology that uses deuterium to change the half-life of the drug and that two of their preclinical compounds are based on that technology platform.

    https://thedalesreport.com/psychedelics/small-pharma-was-established-to-make-medicine-peter-rands-director-and-ceo/
    We’re pleased to welcome to The Dales Report Peter Rands, the Director and CEO of Small Pharma to discuss his company and their focus on DMT.
    We’re pleased to welcome to The Dales Report Peter Rands, the Director and CEO of Small Pharma to discuss his company and their focus on DMT.
    thedalesreport.com
  • j
    j
    Is anybody finding any new information regarding this stock, or is there anybody else talking about this company?
  • i
    i
    What's wrong with this stock?
  • V
    V
    25% drop - no news? Some one is really messing with this stock.
  • C
    Chris
    still has $50M+ in cash? Relatively clean cap table? 86M m. cap? I'll take that bet.
  • J
    JUSTIN
    Anyone know why the 20% drop today? Some bad news that I can’t find?